Discussions with leaders: Johannes Czernin and Ken Herrmann talk with Yaroslav Kmetyuk, head of the All-Ukrainian Radiosurgery Center at the “Feofaniya” Hospital in Kyiv, Ukraine, about challenges in daily practice, including nuclear medicine, during the ongoing war.
Page 1127
SIR-Spheres activity miscalibration: Graves and colleagues report on activity measurements of 90Y SIR-Spheres to determine whether routine calibration provides an accurate estimate of true activity.
Page 1131
FAPI PET in fibrosis: Kuwert and colleagues review current data suggesting fibroblast-activation protein inhibitor agents allow visualization of the dynamics of tissue responses in immune-mediated inflammatory diseases, offering alternatives for early recognition of tissue remodeling in chronic inflammation.
Page 1136
Advances in PET detector instrumentation: Gonzalez-Montoro and colleagues offer an educational overview of the basics of PET detectors, including indirect and direct 511-keV photon detection methods, key detector performance parameters, and technical innovations.
Page 1138
64Cu-DOTA-trastuzumab and T-DM1: Mortimer and colleagues explore the potential of trastuzumab uptake assessment in tumors via PET/CT for identifying patients with metastatic breast cancer who will benefit from treatment with the antibody–drug conjugate trastuzumab–emtansine.
Page 1145
PET/CT in follicular lymphoma without CMR: Barrington and colleagues investigate outcomes in patients in a PET substudy of the prospective phase III GALLIUM trial who did not have complete metabolic response (the sole predictor of overall survival in the study).
Page 1149
68Ga-FAPI-46 and 18F-FDG PET in HNSCC: Promteangtrong and colleagues compare 68Ga–conjugated fibroblast-activation protein inhibitor–46 PET/CT with 18F-FDG PET/CT for detecting primary cancer and metastatic lesions in patients with head and neck squamous cell carcinoma.
Page 1155
Fluorescent sentinel margin detection: Krishnan and colleagues examine the clinical value of fluorescent molecular imaging in real-time identification of the point on a specimen at which the tumor lies closest to the resected edge during frozen section analysis.
Page 1162
uPAR PET in HNSCC: Risør and colleagues report on a phase II clinical trial on the prognostic value of urokinase-type plasminogen activator receptor PET/CT with the novel ligand 68Ga-NOTA-AE105 compared with 18F-FDG in head and neck squamous cell cancer.
Page 1169
Combination hormonal 18F-FDG therapy: Singaravelu and colleagues describe preclinical research on therapeutic enhancement of antiandrogens as radiosensitizers in combination with 18F-FDG in triple-negative breast cancers.
Page 1177
18F-DCFPyL PET/CT in BCR PCa: Mena and colleagues investigate factors predicting prostate-specific membrane antigen–targeted 18F-DCFPyL PET/CT positivity and disease location in patients with biochemical recurrence of prostate cancer after primary local therapy.
Page 1184
PSMA PET for taxane response assessment: Shagera and colleagues evaluate prostate-specific membrane antigen–targeting PET for response and prognostic assessment in metastatic prostate cancer patients treated with taxane-based chemotherapy.
Page 1191
177Lu-PSMA I&T and 177Lu-PSMA-617 PRLT: Schuchardt and colleagues report on the safety, kinetics, and dosimetry of the 177Lu-labeled prostate-specific membrane antigen small molecules 177Lu-PSMA-I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer undergoing PSMA radioligand therapy.
Page 1199
18F-rhPSMA-7 PET in postradiotherapy BCR: Ilhan and colleagues detail a retrospective analysis of the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen–targeting ligand in patients with biochemical recurrence of prostate cancer after curative-intent primary radiotherapy.
Page 1208
TARE vs. resection for large single HCC: Kim and colleagues compare long-term outcomes of transarterial radioembolization with those from resection in patients with large single-nodular hepatocellular carcinomas.
Page 1215
α-Particle radiotherapy for solid tumors: Howe and colleagues combine carriers with complementary microdistributions of delivered α-particles to improve efficacy in established solid tumors even at lower tumor doses.
Page 1223
COVID vaccine and lymph nodes: Seban and colleagues examine the presence of vaccine-induced hypermetabolic lymph nodes on 18F-FDG PET/CT after COVID-19 vaccination and determine their association with lymphocyte counts.
Page 1231
PiB and FMT white matter binding: Przybelski and colleagues compare uptake, distribution, and white matter differentiation assessments of 11C-Pittsburgh compound B and 18F-flutemetamol on PET in a cohort of cognitively normal younger and older adults.
Page 1239
SV2A as a biomarker for SCI: Bertoglio and colleagues conduct preclinical studies on the use of synaptic vesicle glycoprotein 2A PET imaging to detect spinal cord lesions noninvasively after spinal cord injury.
Page 1245
Evaluation of 11C-ER176 analogs: Lee and colleagues use generic 11C labeling and PET in nonhuman primate brain to assess 6 fluorine-containing analogs of ER176 for labeling with longer-lived 18F for 18-kDa translocator protein imaging in neuroinflammation.
Page 1252
Optimizing PD-L1 immuno-PET imaging: Bouleau and colleagues investigate in mice 2 different approaches to designing anti–programmed cell death ligand 1 PET radioligands with optimized pharmacokinetic properties.
Page 1259
Delay correction in total-body PET: Li and colleagues explore the utility of the leading-edge and constant fraction discrimination pulse timing methods to estimate and correct for delay in total-body PET parametric imaging.
Page 1266
Total-body multiparametric PET imaging: Wang and colleagues evaluate the necessity of voxelwise compartmental modeling strategies, including time delay correction and model selection, for total-body multiparametric imaging with quantitative dynamic 18F-FDG PET.
Page 1274
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.